The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 71, Issue , 2016, Pages 108-116

  Uys, Madeleine ^a   Shahid, Mohammed ^b   Sallinen, Jukka ^c   Dreyer, Walter ^a   Cockeran, Marike ^a   Harvey, Brian H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b Orion Corporation   (United Kingdom)

^c ORION CORPORATION   (Finland)

Author keywords

Isolation rearing animal model; Neurodevelopment; Object recognition memory; Sensorimotor gating; Typical vs. atypical antipsychotic; 2C Adrenoceptor

Indexed keywords

1 METHOXYMETHYL 1 (BETA) METHYL 1,3,4,5,6,11B(ALPHA)HEXAHYDRO 2H 11 OXA 4A AZA BENZO[A]FLUORINE; ALPHA 2C ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; ORM-10921; QUINOLIZIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXPLORATORY BEHAVIOR; MALE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; SENSORY GATING; SOCIAL CONTROL; SOCIAL ISOLATION; STARTLE REFLEX; TREATMENT RESPONSE; ANIMAL; AUDITORY STIMULATION; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PSYCHOLOGY; RECOGNITION; SPRAGUE DAWLEY RAT;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOFURANS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HALOPERIDOL; MALE; PREPULSE INHIBITION; QUINOLIZIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ISOLATION; STATISTICS, NONPARAMETRIC;

EID: 84978766002     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.07.002     Document Type: Article

References (115)

1. Andreassen, O.A., Ferrante, R.J., Beal, M.F., Jørgensen, H.A., Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience 87 (1998), 639–648.
2. Antunes, M., Biala, G., The novel object recognition memory: Neurobiology, test procedure, and its modifications. Cogn. Process. 13 (2012), 93–110.
3. Arnsten, A.F.T., Leslie, F.M., Behavioral and receptor binding analysis of the α2-adrenergic agonist, 5-bromo-6 [2-imidazoline-2-YL amino] quinoxaline (UK-14,304): evidence for cognitive enhancement at an α2-adrenoceptor subtype. Neuropharmacology 30 (1991), 1279–1289.
4. Arnsten, A.F.T., Cai, J.X., Murphy, B.L., Goldman-Rakic, P.S., Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116 (1994), 143–151.
5. Autry, A.E., Monteggia, L.M., Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64 (2012), 238–258.
6. Babin, S.L., Hood, A.J., Wassef, A.A., Williams, N.G., Patel, S.S., Sereno, A.B., Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 (2011), 1753–1764.
7. Bakshi, V.P., Swerdlow, N.R., Geyer, M.A., Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994), 787–794.
8. Baldessarini, R.J., Huston-Lyons, D., Campbell, A., Marsh, E., Cohen, B.M., Do central antiadrenergic actions contribute to the atypical properties of clozapine?. Br. J. Psychiatry 160:Suppl. 17 (1992), 12–16.
9. Binder, E.B., Kinkead, B., Owens, M.J., Kilts, C.D., Nemeroff, C.B., Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating. J. Neurosci. 21 (2001), 601–608.
10. Björklund, M., Sirviö, J., Riekkinen, M., Sallinen, J., Scheinin, M., Riekkinen, P. Jr., Overexpression of Alpha2C-adrenoceptors impairs water maze navigation. Neuroscience 95 (1999), 481–487.
11. Björklund, M., Sirviö, J., Sallinen, J., Scheinin, M., Kobilka, B.K., Riekkinen, P. Jr., Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns. Neuroscience 88 (1999), 1187–1198.
12. Björklund, M., Sirviö, J., Puoliväli, J., Sallinen, J., Jäkälä, P., Scheinin, M., Kobilka, B.K., Riekkinen, P. Jr., α(2C)-Adrenoceptor-overexpressing mice are impaired in executing nonspatial and spatial escape strategies. Mol. Pharmacol. 54 (1998), 569–576.
13. Björklund, M., Siverina, I., Heikkinen, T., Tanila, H., Sallinen, J., Scheinin, M., Fuekkinen, P. Jr., Spatial working memory improvement by an α2-adrenoceptor agonist dexmedetomidine is not mediated through α2C-adrenoceptor. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 (2001), 1539–1554.
14. Bowie, C.R., Harvey, P.D., Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr. Dis. Treat. 2 (2006), 531–536.
15. Braff, D.L., Geyer, M.A., Sensorimotor gating and schizophrenia human and animal model studies. Arch. Gen. Psychiatry 47 (1990), 181–188.
16. Braff, D.L., Grillon, C., Geyer, M.A., Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49 (1992), 206–215.
17. Broadbent, N.J., Gaskin, S., Squire, L.R., Clark, R.E., Object recognition memory and the rodent hippocampus. Learn. Mem. 17 (2010), 794–800.
18. Buckley, P.F., Mahadik, S., Pillai, A., Terry, A. Jr., Neurotrophins and schizophrenia. Schizophr. Res. 94 (2007), 1–11.
19. Buckley, P.F., Pillai, A., Evans, D., Stirewalt, E., Mahadik, S., Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 91 (2007), 1–5.
20. Cai, J.X., Ma, Y.Y., Xu, L., Hu, X.T., Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha 2-adrenergic agonist clonidine. Brain Res. 614 (1993), 191–196.
21. Carlson, S., Tanila, H., Rama, P., Mecke, E., Pertovaara, A., Effects of medetomidine, an α-2 adrenoceptor agonist, and atipamezole, an α-2 antagonist, on spatial memory performance in adult and aged rats. Behav. Neural Biol. 58 (1992), 113–119.
22. Castner, S.A., Williams, G.V., Goldman-Rakic, P.S., Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287 (2000), 2020–2022.
23. Chakos, M.H., Schobel, S.A., Gu, H., Gerig, G., Bradford, D., Charles, C., Lieberman, J.A., Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 186 (2005), 26–31 (JAN.).
24. Dalgalarrondo, P., Gattaz, W.F., Basal ganglia abnormalities in tardive dyskinesia - Possible relationship with duration of neuroleptic treatment. Eur. Arch. Psychiatry Clin. Neurosci. 244 (1994), 272–277.
25. Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W.W., Keefe, R.S., Boter, H., Keet, I.P.M., Prelipceanu, D., Rybakowski, J.K., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., Kahn, R.S., Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 166 (2009), 675–682.
26. Dawson, M.E., Schell, A.M., Hazlett, E.A., Nuechterlein, K.H., Filion, D.L., On the clinical and cognitive meaning of impaired sensorimotor gating in schizophrenia. Psychiatry Res. 96 (2000), 187–197.
27. Depoortere, R., Perrault, G., Sanger, D.J., Potentiation of prepulse inhibition of the startle reflex in rats: Pharmacological evaluation of the procedure as a model for detecting antipsychotic activity. Psychopharmacology 132 (1997), 366–374.
28. Elsworth, J.D., Groman, S.M., Jentsch, J.D., Valles, R., Shahid, M., Wong, E., Marston, H., Roth, R.H., Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 62 (2012), 1442–1452.
29. Ennaceur, A., Delacour, J., A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav. Brain Res. 31 (1988), 47–59.
30. Erasmus, M., Shahid, M., Sallinen, J., Harvey, B.H., Selective α2C-adrenoceptor antagonism with ORM-10921 decreases behavioural despair and improves cognition in the Flinders Sensitive Line rat model of depression. In: Poster presented at the 28th European College of Neuropsychopharmacology Congress, 2015, Amsterdam, Netherlands 29 August – 1 September 2015.
31. Farde, L., Nordström, A.L., PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatry. Suppl. 17 (1992), 30–33.
32. Farde, L., Wiesel, F.A., Nordström, A.L., Sedvall, G., D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology Suppl. 99 (1989), S28–S31.
33. Favalli, G., Li, J., Belmonte-de-Abreu, P., Wong, A.H.C., Daskalakis, Z.J., The role of BDNF in the pathophysiology and treatment of schizophrenia. J. Psychiatr. Res. 46 (2012), 1–11.
34. Fone, K.C., Porkess, M.V., Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci. Biobehav. Rev. 32 (2008), 1087–1102.
35. Franowicz, J.S., Kessler, L.E., Dailey Borja, C.M., Kobilka, B.K., Limbird, L.E., Arnsten, A.F.T., Mutation of the α2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22 (2002), 8771–8777.
36. Gacsályi, I., Nagy, K., Pallagi, K., Lévay, G., Hársing, L.G. Jr., Móricz, K., Kertész, S., Varga, P., Haller, J., Gigler, G., Szénási, G., Barkóczy, J., Bíró, J., Spedding, M., Antoni, F.A., Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology 64 (2013), 254–263.
37. Geyer, M.A., Braff, D.L., Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr. Bull. 13 (1987), 643–668.
38. Geyer, M.A., Swerdlow, N.R., Measurement of startle response, prepulse inhibition, and habituation. Curr. Protoc. Neurosci., 2001, John Wiley & Sons, Inc., 10.1002/0471142301.ns0807s03 (Chapter 8, Unit 8.7).
39. Geyer, M.A., Wilkinson, L.S., Humby, T., Robbins, T.W., Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol. Psychiatry 34 (1993), 361–372.
40. Guillaume, F., Thomas, E., Faget, C., Richieri, R., Lançon, C., Perceptually or conceptually driven recognition: on the specificities of the memory deficit in schizophrenia. Psychiatry Res. 225 (2015), 493–500.
41. 2 antagonist haloperidol. Behav. Brain Res. 177 (2007), 364–367.
42. Harvey, B.H., Stein, D.J., Emsley, R.A., The new-generation antipsychotics — integrating the neuropathology and pharmacology of schizophrenia. S. Afr. Med. J. 89 (1999), 661–672.
43. Heidbreder, C.A., Weiss, I.C., Domeney, A.M., Pryce, C., Homberg, J., Hedou, G., Feldon, J., Moran, M.C., Nelson, P., Behavioral, neurochemical and endocrinological characterization of the early social isolation syndrome. Neuroscience 100 (2000), 749–768.
44. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402 (1999), 181–184.
45. 2 adrenoceptor blockade. Science 286 (1999), 105–107.
46. Hertel, P., Nomikos, G.G., Svensson, T.H., Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur. J. Pharmacol. 371 (1999), 153–158.
47. Horiguchi, M., Hannaway, K.E., Adelekun, A.E., Jayathilake, K., Meltzer, H.Y., Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by Co-administration of lurasidone or tandospirone, a 5-HT 1A partial agonist. Neuropsychopharmacology 37 (2012), 2175–2183.
48. Ishiwari, K., Madson, L.J., Farrar, A.M., Mingote, S.M., Valenta, J.P., DiGianvittorio, M.D., Frank, L.E., Correa, M., Hockemeyer, J., Müller, C., Salamone, J.D., Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav. Brain Res. 178 (2007), 190–199.
49. Jones, C., Watson, D., Fone, K., Animal models of schizophrenia. Br. J. Pharmacol. 164 (2011), 1162–1194.
50. Kahn, R.S., Keefe, R.S.E., Schizophrenia is a cognitive illness: Time for a change in focus. JAMA Psychiatry 70 (2013), 1107–1112.
51. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur. J. Pharmacol. 462 (2003), 33–40.
52. Kapur, S., Arenovich, T., Agid, O., Zipursky, R., Lindborg, S., Jones, B., Evidence for onset of antipsychotic effects within the first 24 h of treatment. Am. J. Psychiatry 162 (2005), 939–946.
53. Kapur, S., Zipursky, R., Jones, C., Shammi, C.S., Remington, G., Seeman, P., A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry 57 (2000), 553–559.
54. Keefe, R.S.E., Seidman, L.J., Christensen, B.K., Hamer, R.M., Sharma, T., Sitskoorn, M.M., Lewine, R.R.J., Yurgelun-Todd, D.A., Gur, R.C., Tohen, M., Tollefson, G.D., Sanger, T.M., Lieberman, J.A., Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161 (2004), 985–995.
55. King, M.V., Seeman, P., Marsden, C.A., Fone, K.C.F., Increased dopamine D2 high receptors in rats reared in social isolation. Synapse 63 (2009), 476–483.
56. Kusljic, S., Brosda, J., Van Den Buuse, M., Effects of haloperidol and clozapine on sensorimotor gating deficits induced by 5-hydroxytryptamine depletion in the brain. Br. J. Pharmacol. 147 (2006), 800–807.
57. Le Pen, G., Moreau, J.L., Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: Reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 27:1 (2002), 1–11.
58. Li, L., Du, Y., Li, N., Wu, X., Wu, Y., Top-down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci. Biobehav. Rev. 33 (2009), 1157–1167.
59. Lipska, B.K., Weinberger, D.R., Swerdlow, N.R., Geyer, M.A., Braff, D.L., Jaskiw, G.E., Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122 (1995), 35–43.
60. 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J. Clin. Psychopharmacol. 13 (1993), 264–267.
61. Litman, R.E., Su, T.P., Potter, W.Z., Hong, W.W., Pickar, D., Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry 168 (1996), 571–579.
62. 2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int. J. Neuropsychopharmacol. 8 (2005), 315–327.
63. Marcus, M.M., Wiker, C., Franberg, O., Konradsson-Geuken, A., Langlois, X., Jardemark, K., Svensson, T.H., Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int. J. Neuropsychopharmacol. 13 (2010), 891–903.
64. McLean, S.L., Grayson, B., Harris, M., Protheroe, C., Bate, S., Woolley, M.L., Neill, J.C., Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats. J. Psychopharmacol. 24 (2010), 57–63.
65. McMillen, B.A., Shore, P.A., Comparative effects of clozapine and α-adrenoceptor blocking drugs on regional noradrenaline metabolism in rat brain. Eur. J. Pharmacol. 52 (1978), 225–230.
66. Millan, M.J., Goodwin, G.M., Meyer-Lindenberg, A., Ove Ogren, S., Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 25 (2015), 599–656.
67. Mion, C.C., Andreasen, N.C., Arndt, S., Swayze Ii, V.W., Cohen, G.A., MRI abnormalities in tardive dyskinesia. Psychiatry Res. 40 (1991), 157–166.
68. Mishara, A.L., Goldberg, T.E., A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry 55 (2004), 1013–1022.
69. Moghaddam, B., Bunney, B.S., Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J. Neurochem. 54 (1990), 1755–1760.
70. Möller, M., Du Preez, J.L., Emsley, R., Harvey, B.H., Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. Eur. Neuropsychopharmacol. 21 (2011), 471–483.
71. Möller, M., Du Preez, J.L., Emsley, R., Harvey, B.H., Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. Neuropharmacology 62 (2012), 2499–2506.
72. Möller, M., Du Preez, J.L., Viljoen, F.P., Berk, M., Emsley, R., Harvey, B.H., Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behav. Immun. 30 (2013), 156–167.
73. Natesan, S., Reckless, G.E., Barlow, K.B.L., Nobrega, J.N., Kapur, S., Evaluation of N-desmethylclozapine as a potential antipsychotic — preclinical studies. Neuropsychopharmacology 32 (2007), 1540–1549.
74. Natesan, S., Reckless, G.E., Barlow, K.B.L., Nobrega, J.N., Kapur, S., Amisulpride the ‘atypical’ atypical antipsychotic — comparison to haloperidol, risperidone and clozapine. Schizophr. Res. 105 (2008), 224–235.
75. Nel, A., Harvey, B.H., Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav. Pharmacol. 14 (2003), 251–255.
76. Nieto, R., Kukuljan, M., Silva, H., BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front. Psychiatry., 4, 2013, 45.
77. Pedrini, M., Chendo, I., Grande, I., Lobato, M.I., Belmonte-de-Abreu, P.S., Lersch, C., Walz, J., Kauer-Sant'Anna, M., Kapczinski, F., Gama, C.S., Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci. Lett. 491 (2011), 207–210.
78. Pickar, D., Owen, R.R., Litman, R.E., Konicki, P.E., Gutierrez, R., Rapaport, M.H., Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch. Gen. Psychiatry 49 (1992), 345–353.
79. Pillai, A., Terry, A.V. Jr., Mahadik, S.P., Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 82 (2006), 95–106.
80. Polacchini, A., Metelli, G., Francavilla, R., Baj, G., Florean, M., Mascaretti, L.G., Tongiorgi, E., A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Sci. Rep., 5, 2015, 17989.
81. Powell, S.B., Geyer, M.A., Developmental markers of psychiatric disorders as identified by sensorimotor gating. Neurotox. Res. 4 (2002), 489–502.
82. Raudenska, M., Gumulec, J., Babula, P., Stracina, T., Sztalmachova, M., Polanska, H., Adam, V., Kizek, R., Novakova, M., Masarik, M., Haloperidol cytotoxicity and its relation to oxidative stress. Mini-Rev. Med. Chem. 13 (2013), 1993–1998.
83. Redrobe, J.P., Bull, S., Plath, N., Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front. Psychiatry., 1(NOV), 2010, 146.
84. Reynolds, G.P., The neurochemistry of schizophrenia. Psychiatry 7 (2008), 425–429.
85. Rosin, D.L., Talley, E.M., Lee, A., Stornetta, R.L., Gaylinn, B.D., Guyenet, P.G., Lynch, K.R., Distribution of α(2C)-adrenergic receptor-like immunoreactivity in the rat central nervous system. J. Comp. Neurol. 372 (1996), 135–165.
86. Rouru, J., Wesnes, K., Hänninen, J., Murphy, M., H., R., Rinne, J.O., A 12-week proof-of-concept efficacy and safety study of ORM-12,741 in patients with moderate Alzheimer's disease. Poster Presented at the International Society for CNS Clinical Trials and Methodology Autumn Conference, Philadelphia, USA, 30 September–2 October, 2013.
87. Sallinen, J., Holappa, J., Koivisto, A., Kuokkanen, K., Chapman, H., Lehtimäki, J., Piepponen, P., Mijatovic, J., Tanila, H., Virtanen, R., Sirviö, J., Haapalinna, A., Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin. Pharmacol. Toxicol. 113 (2013), 239–249.
88. Sallinen, J., Rouru, J., Lehtimäki, J., Marjamäki, P., Haaparanta-Solin, M., Arponen, E., Helin, S., et al. ORM-12741: receptor pharmacology of a novel alpha 2C-adrenergic receptor subtype selective antagonist with multi-therapeutic potential. Neuropsychopharmacology, 38, 2013, S558, 10.1038/npp.2013.281.
89. Sallinen, J., Höglund, I., Engström, M., Lehtimäki, J., Virtanen, R., Sirviö, J., Wurster, S., Savola, J.M., Haapalinna, A., Pharmacological characterization and CNS effects of a novel highly selective α 2C-adrenoceptor antagonist JP-1302. Br. J. Pharmacol. 150 (2007), 391–402.
90. Sawaguchi, T., Goldman-Rakic, P.S., The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71 (1994), 515–528.
91. Scheinin, M., Lomasney, J.W., Hayden-Hixson, D.M., Schambra, U.B., Caron, M.G., Lefkowitz, R.J., Fremeau, R.T. Jr., Distribution of α2-adrenergic receptor subtype gene expression in rat brain. Mol. Brain Res. 21 (1994), 133–149.
92. Shahid, M., Walker, G.B., Zorn, S.H., Wong, E.H.F., Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23 (2009), 65–73.
93. Sharma, T., Hughes, C., Soni, W., Kumari, V., Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology 169 (2003), 398–403.
94. Sigurdsson, T., Neural circuit dysfunction in schizophrenia: insights from animal models. Neuroscience 321 (2016), 42–65.
95. Singh, S., Parikh, T., Sandhu, H.K., Shah, N.H., Malick, A.W., Singhal, D., Serajuddin, A.T.M., Supersolubilization and amorphization of a model basic drug, haloperidol, by interaction with weak acids. Pharm. Res. 30 (2013), 1561–1573.
96. Snigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J.C., Meltzer, H.Y., Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine2A receptor inverse agonist. J. Pharmacol. Exp. Ther. 332 (2010), 622–631.
97. Starke, K., Presynaptic autoreceptors in the third decade: focus on α2-adrenoceptors. J. Neurochem. 78 (2001), 685–693.
98. Steen, R.G., Mull, C., McClure, R., Hamer, R.M., Lieberman, J.A., Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 188 (2006), 510–518.
99. Svensson, T.H., α-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003), 1145–1158.
100. Swartz, M.S., Perkins, D.O., Stroup, T.S., McEvoy, J.P., Nieri, J.M., Haak, D.C., Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. Schizophr. Bull. 29 (2003), 33–43.
101. Swartz, M.S., Wagner, H.R., Swanson, J.W., Stroup, T.S., McEvoy, J.P., Reimherr, F., Miller, D.D., McGee, M., Khan, A., Canive, J.M., Davis, S.M., Hsiao, J.K., Lieberman, J.A., The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr. Res. 100 (2008), 39–52.
102. Tan, Y.L., Zhou, D.F., Zhang, X.Y., Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 74 (2005), 263–270.
103. Tost, H., Braus, D.F., Hakimi, S., Ruf, M., Vollmert, C., Hohn, F., Meyer-Lindenberg, A., Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat. Neurosci. 13 (2010), 920–922.
104. Toua, C., Brand, L., Möller, M., Emsley, R.A., Harvey, B.H., The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats. Neuroscience 165 (2010), 492–499.
105. Tsapakis, E.M., Dimopoulou, T., Tarazi, F.I., Clinical management of negative symptoms of schizophrenia: an update. Pharmacol. Ther. 153 (2015), 135–147.
106. Van den Buuse, M., Eikelis, N., Estrogen increases prepulse inhibition of acoustic startle in rats. Eur. J. Pharmacol. 425 (2001), 33–41.
107. Varty, G.B., Higgins, G.A., Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology 122 (1995), 15–26.
108. Vollenweider, F.X., Barro, M., Csomor, P.A., Feldon, J., Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol. Psychiatry 60 (2006), 597–603.
109. Wadenberg, M.L.G., Soliman, A., VanderSpek, S.C., Kapur, S., Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001), 633–641.
110. Wadenberg, M.L., Wiker, C., Svensson, T.H., Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int. J. Neuropsychopharmacol. 10 (2007), 191–202.
111. Wang, J.H., Short, J., Ledent, C., Lawrence, A.J., Van Den Buuse, M., Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav. Brain Res. 143 (2003), 201–207.
112. Westerink, B.H.C., Kawahara, Y., De Boer, P., Geels, C., De Vries, J.B., Wikström, H.V., Van Kalkeren, A., Van Vliet, B., Kruse, C.G., Long, S.K., Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412 (2001), 127–138.
113. Young, J.W., Powell, S.B., Risbrough, V., Marston, H.M., Geyer, M.A., Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122 (2009), 150–202.
114. Zhang, W., Klimek, V., Farley, J.T., Zhu, M.Y., Ordway, G.A., α(2C) adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J. Pharmacol. Exp. Ther. 289 (1999), 1286–1292.
115. Zhang, W., Pouzet, B., Jongen-Rêlo, A.L., Weiner, I., Feldon, J., Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics. NeuroReport 10 (1999), 2533–2538.